Document is current
Any future updates will be listed below
-
Authors
Wang, Xiangxue
Janowczyk, Andrew
Zhou, Yu
Thawani, Rajat
Fu, Pingfu
Schalper, Kurt
Velcheti, Vamsidhar
Madabhushi, Anant
- License Information
-
More Information
Article History
Received: 16 February 2017
Accepted: 2 October 2017
First Online: 19 October 2017
Competing Interests
: Xiangxue Wang, Andrew Janowczyk, Yu Zhou, Rajat Thawani and Pingfu Fu have no conflicts to declare. Dr. Schalper is a Consultant for Viralytics. He has received research funding from Genoptix (Novartis), Vasculox, Tesaro, Onkaido Therapeutics and Takeda Pharmaceuticals. Dr. Velcheti is a Consultant for Clovis Oncology, Genertech, Bristol-Myers Squibb, Merck, Celgene, Foundation Medicine, AstraZeneca/MedImmune and Genoptix. He has received research funding from Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics and Leap Therapeutics. Dr. Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. He is also a scientific advisory consultant for Inspirata Inc and also sits on its scientific advisory board. He is also an equity holder in Inspirata Inc. Additionally his technology has been licensed to Elucid Bioimaging and Inspirata Inc. He is also involved in a NIH U24 grant with PathCore Inc. His work is also partially sponsored by Philips Healthcare.
